HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats.

Abstract
We have previously reported that selective dopamine (DA) D3 receptor antagonists are effective in a number of animal models of drug addiction, but not in intravenous drug self-administration, suggesting a limited ability to modify drug reward. In the present study, we evaluated the actions ofS33138, a novel partially selective D3 receptor antagonist, in animal models relevant to drug addiction. S33138, at doses of 0.156 or 0.625 mg/kg (i.p.), attenuated cocaine-enhanced brain-stimulation reward (BSR), and the highest dose tested (2.5 mg/kg) produced a significant aversive-like rightward shift in BSR rate-frequency reward functions. Further, S33138 produced biphasic effects on cocaine self-administration, i.e., a moderate dose (2.5 mg/kg, p.o.) increased, while a higher dose (5 mg/kg, p.o.) inhibited, cocaine self-administration. The increase in cocaine self-administration likely reflects a compensatory response to a partial reduction in drug reward after S33138. In addition, S33138 (0.156-2.5 mg/kg, p.o.) also dose-dependently inhibited cocaine-induced reinstatement of drug-seeking behavior. The reduction in cocaine-enhanced BSR and cocaine-triggered reinstatement produced by lower effective doses (e.g., 0.156 or 0.625 mg/kg) of 533138 is unlikely due to impaired locomotion, as lower effective doses of S33138 decreased neither Ymax levels in the BSR paradigm, rotarod performance, nor locomotion. However, the higher doses (2.5 or 5 mg/kg) of S33138 also significantly inhibited sucrose self-administration and rotarod performance, suggesting non-D3 receptor-mediated effects on non-drug reward and locomotion. These data suggest that lower doses of S33138 interacting essentially with D3 receptors have pharmacotherapeutic potential in treatment of cocaine addiction, while higher doses occupying D2 receptors may influence locomotion and non-drug reward.
AuthorsXiao-Qing Peng, Charles R Ashby Jr, Krista Spiller, Xia Li, Jie Li, Nitza Thomasson, Mark J Millan, Elisabeth Mocaër, Carmen Muńoz, Eliot L Gardner, Zheng-Xiong Xi
JournalNeuropharmacology (Neuropharmacology) Vol. 56 Issue 4 Pg. 752-60 (Mar 2009) ISSN: 1873-7064 [Electronic] England
PMID19136017 (Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Acetanilides
  • Benzopyrans
  • Dopamine Antagonists
  • Dopamine Uptake Inhibitors
  • N-(4-(2-(8-cyano-1,3a,4,9b-tetrahydro(1)benzopyrano(3,4-c)pyrrol-2(3H)-yl)ethyl)phenyl)acetamide
  • Receptors, Dopamine D3
  • Sucrose
  • Cocaine
Topics
  • Acetanilides (pharmacology)
  • Animals
  • Benzopyrans (pharmacology)
  • Cocaine (administration & dosage, antagonists & inhibitors, pharmacology)
  • Cocaine-Related Disorders (drug therapy, psychology)
  • Dopamine Antagonists (pharmacology)
  • Dopamine Uptake Inhibitors (administration & dosage, antagonists & inhibitors, pharmacology)
  • Dose-Response Relationship, Drug
  • Electric Stimulation
  • Extinction, Psychological (drug effects)
  • Injections, Intravenous
  • Male
  • Motor Activity (drug effects)
  • Postural Balance (drug effects)
  • Psychomotor Performance (drug effects)
  • Rats
  • Rats, Long-Evans
  • Receptors, Dopamine D3 (antagonists & inhibitors)
  • Recurrence
  • Reinforcement Schedule
  • Self Administration
  • Self Stimulation
  • Sucrose (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: